Teva Pharmaceutical Industries is a global pharmaceutical company that develops, produces, and markets affordable generic and specialty medicines, with a leading position in generic drugs and a growing specialty portfolio focused on central nervous system disorders, immunology, and respiratory conditions.
Planned closure of Fairfield, NJ solid oral-dose manufacturing facility (61 roles affected)
Q3 2026 Earnings & Pivot to Growth strategic optimization update
Teva Pharmaceutical Industries filed a New Jersey WARN Act notice disclosing 61 layoffs and the permanent closure of its solid oral-dose manufacturing plant in Fairfield, New Jersey by January 31, 2027 (effective February 1, 2027). The facility shutdown is part of CEO Richard Francis's multi-year 'Pivot to Growth' operational realignment, which aims to phase out underutilized, high-overhead production footprints facing generic price erosion while reallocating manufacturing capital toward biosimilars and core commercial brands like Austedo and Ajovy.
Teva initiated approximately 250 layoffs at its active pharmaceutical ingredient (API) manufacturing business alongside broader multi-year workforce reductions across its generics and specialty operations.
Teva Pharmaceutical Industries filed a New Jersey WARN Act notice disclosing 61 layoffs and the permanent closure of its solid oral-dose manufacturing facility in Fairfield, NJ by January 31, 2027, as part of CEO Richard Francis's 'Pivot to Growth' cost-efficiency strategy.
Fierce Pharma takes a closer look inside Teva's Weltruza launch and Novo Nordisk's GLP-1 strategy.
Teva's CEO said the company has time to prepare for the incoming tariffs on generic drugs manufactured outside the U.S., expressing confidence in its ability to brace for the impact.
Teva Pharmaceutical Industries is laying off approximately 250 employees at its active pharmaceutical ingredient (API) manufacturing unit, which the company is seeking to divest as part of an ongoing restructuring.